Among @,@ patients who received study medication , @,@ ( @ % ) received clopidogrel before randomization , of whom @ % stopped later in the trial ( median time to stoppage @ days with placebo ; interquartile range -LSB- IQR -RSB- @-@ ) ( @ days with vorapaxar ; IQR @-@ ) .